tbuckley/cabot-search huggingface dataset:
Abstract 16928: Impact of Statin Therapy on Dynamic and Static Measures of Autonomic Tone in Patients with Hypertrophic Cardiomyopathy
Authors: R. Cameron Herman, Mina Girgis, Taz Vira, Robert S Sheldon, Peter Giannoccarro, Andrew G Howarth, Maureen McRae, Linda Ellis, Michael P Slawnych, Derek V Exner, Sircat Investigators
Journal: Circulation (2012)

Background: Heart rate turbulence (HRT) measures dynamic changes in the autonomic nervous system, while the Standard Deviation of NN intervals (SDNN) reflects resting autonomic tone. The pleiotropi...
Abstract 271: Detection of Ventricular Fibrillation with Continuing Chest Compression Using Adaptive Least Mean-Square Estimation of Cardiopulmonary Resuscitation Artifacts and Removal of the Artifacts
Authors: Chen Lin, Patrick Chow-In Ko, Men-Tzung Lo, Wen-Chu Chiang, Wan-Hsin Hsieh, Lian-Yu Lin, Chien-Hua Huang, Jiunn-Lee Lin, Wen-Jone Chen, Matthew Huei-Ming Ma
Journal: Circulation (2012)

Introduction: Adequate perfusion during cardiopulmonary resuscitation (CPR) is crucial for successful defibrillation after ventricular fibrillation (VF), but the effects of chest compressions (CC) are compromised from interruptions due to rhythm analysis. A novel algorithm utilizing corrupted ECG signal to detect VF during continuing CC is developed. Method: VF waveforms were retrieved from automatic external defibrillator (AED) records of adult non-traumatic cardiac arrests. Ten CC artifacts were retrieved from arrests with asystole. Corrupted ECG was constructed by adding a scaled CC artifact to a VF with strength determined by signal-to-interference ratio (SIR). Using empirical mode decomposition, the fluctuation and frequency of CC were retrieved. VF was detected by subtracting the CC artifacts, modeled by least mean-square (LMS) algorithm, from ECG signals. Amplitude spectrum analysis (AMSA) was used to quantify the component with frequency range 0.7[[Unable to Display Character: ‐]]30 Hz. Result: One-hundred and fifty VF (36 successful and 114 unsuccessful defibrillation, p&lt;0.01) were included. After removing CC artifacts with the algorithm, successful vs unsuccessful cases remained distinguished (p&lt;0.05) in SIR ranged 0 to -9dB. The detected and the original VFs had similar AMSA with correlation of 0.98, 0.95, 0.93 and 0.86 when SIR were 0, -3, -6 and -9dB (p&lt;0.001). The mean of difference between the detected VFs and the original VFs were 0.19, 0.56, 1.36 and 3.33 for SIR of 0, -3, -6 and -9dB, respectively, in Bland-Altman plot. Conclusions: The proposed adaptive algorithm using LMS could model CPR artifact without external signals, and effectively detect VF with continuing CC.
The impact of PET-CT fusion on radiation treatment planning in patients with gastrointestinal tumors
Authors: J. C. Landry, M. Koshy, S. Ghavidel, C. Anderson, N. Esiashvili, L. W. Davis
Journal: Journal of Clinical Oncology (2004)

3636 Background: From 03/03 to 11/03, we prospectively evaluated the impact of PET scans on radiation treatment volumes when compared to CT scans in 25 patients with Gastrointestinal (GI)tumors. Methods : 18 patients were scanned on our GE Big Bore PET-CT scanner(PET aperture 70cm) and 7 on our standard aperture GE-PET-CT scanner. CT-PET images were automatically registered with PET-CT fusion software. Primary site was esophageal in 5, rectal in 18 and anal canal in 2 patients. Patients with rectal cancer received preoperative chemoradiation and all others received definitive chemoradiation. All patients were immobilized and scanned in treatment position and received 3-D conformal radiation . We are reporting findings in 18 of the 25 patients. One physician contoured CT Gross Tumor Volume(CT-GTV) and then the PET Gross Tumor Volume(PET-GTV). The PET and CT volumes were measured in cubic centimeters and percent overlap volume (POV) was analyzed. Results : In esophageal cancer patients the POV ranged from 20%–61%(mean 42.25%). In the 12 patients with rectal cancer, POV ranged from 11%–69%(mean 40.25% ). In patients with anal canal tumors, POV was 59%–99%(mean79%) . In 4/18 patients(22%), PET resulted in a change in the treatment planning volume; 2/4(50%)esophageal, 1/2(50%) anal canal and 1/12(8%)rectal tumors. In 30% to 80% of patients, PET suggested additional volume of tumor compared to CT alone. Conclusion: The addition of PET-CT fusion to the treatment planning process in GI tumors is important. The variation in volume was significant in 22% of patients resulting in a change in the treatment fields. The wide variation in tumor volume could have important implications in IMRT treatment planning where tighter margins are often used. We have obtained post treatment PET-CT scans in patients with rectal cancer and are correlating the findings with post resection pathological specimens. The sensitivity of PET-CT after chemoradiation will be discussed. No significant financial relationships to disclose.
Radiation and chemotherapy sensitization with a cox-2 inhibitor in treatment of cancer of the head and neck
Authors: J. George, L. M. Nabell, G. Peters, W. Carroll, R. Ove
Journal: Journal of Clinical Oncology (2004)

5542 Background: Unresectable squamous cell carcinomas of the head and neck (SCCHN) pose a therapeutic challenge with 5-year disease free survival rates in the range of 20–60%. Recent series have supported a survival advantage of chemoradiation for locally advanced disease. Concurrent chemoradiation with carboplatin and paclitaxel has achieved a clinical complete response (CR) rate in 75% of locally advanced SCCHN, with tolerable toxicity. Celecoxib has been shown to be a potent radiosensitizer, and can enhance the activity of certain chemotherapeutic agents. This report evaluates the toxicity and response to Celecoxib administered concurrently with carboplatin, paclitaxel, and radiation therapy in patients with locally advanced SCCHN, compared to a group of patients treated in a similar fashion without Celecoxib. Methods: We conducted a Phase IB/II trial of celecoxib given concurrently with chemoradiation, for locally advanced SCCHN. Patients with stage III/IV nonmetastatic SCCHN were treated with weekly carboplatin, paclitaxel, and concurrent radiotherapy. Carboplatin was dosed at AUC=2.0, paclitaxel at 30–45 mg/m2 and Celecoxib was given at 400mg bid on each day of radiotherapy. Results: Twenty patients (10 per group) were evaluable for toxicity and response. The majority of patients receiving Celecoxib completed the prescribed therapy, although 5 patients required treatment breaks due to hematologic toxicity (2 grade 4 ANC, 2 grade3–4 neutropenic fever (NF), and 1 grade 3 thrombocytopenia). Four patients underwent radiation breaks, and 2 were removed from the study because of toxicity. Eighty percent of the patients in the non-Celecoxib group completed chemotherapy, though 3 had treatment held and 2 required radiation breaks (1 grade 3 ANC, and 1 grade 3 NF). No patients exhibited progression of disease. There was a trend for greater myelosuppression in the group receiving Celecoxib. Conclusions: Weekly carboplatin and paclitaxel given concurrent with definitive radiation is a well-tolerated and efficacious regimen. The addition of Celecoxib engendered greater myelosuppression despite the use of relatively low dose chemotherapy. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb; Pfizer
Diagnostic sub-classification of non-small cell lung cancer: Importance in clinical therapeutics and prognostication
Authors: M. J. Donovan, A. Kotsianti, A. Colomer, M. Verdu, M. Clayton, H. Pang, S. Hamann, C. Cordon-Cardo, X. Puig
Journal: Journal of Clinical Oncology (2005)

9597 Background: The association of EGFR mutations with bronchoalveolar carcinoma (BAC)/non-small cell lung cancer (NSCLC) and the therapeutic and prognostic variability reported for lung cancer has reinforced the need for more accurate NSCLC sub-classification. The present study utilizes clinical data, immunohistochemistry (IHC), molecular analyses, and quantified immunofluorescent multiplexing (QIFM) to develop a systems pathology model for NSCLC. Methods: 73 NSCLC cases; 64 males/9 females were compiled (including whole sections) for Tissue Micro Array (TMA) generation: 34 adenocarcinoma (ACA), 27 squamous cell carcinoma (SCC), 3 adenosquamous carcinoma (ASC), 5 large cell undifferentiated carcinoma (LCC), and 1 BAC. Diagnostic assessment, for both whole sections and TMA, included histology and IHC with a panel of antibodies: EGFR (clones E30 and 31G7), cytokeratins (CK7, 20 and 5/6), and thyroid transcription factor (TTF1). In addition, EGFR mutation analysis was performed utilizing previously published primers. Data from QIFM with CK 18, pKDR and pERK was also collected. Results: Twenty out of 70 cases (29%) required re-categorization, 19 reclassified according to the IHC profiles and one based on morphology. EGFR IHC with clone 31G7 was more robust than E30, SCC tumors exhibiting a higher score (2–3+ overall) compared to AC. EGFR mutation in exon 19 was identified in one BAC tumor sample (female) out of 31 cases evaluated. Two tumor samples (ASC and AC) contained intronic point mutations. Conclusion: The integration of clinical data, IHC profiles, EGFR status and additional marker studies (QIFM) has generated an improved model for NSCLC classification. This further demonstrates the benefit of a systems pathology approach, integrating biomarker analysis, clinical data, molecular assays and image based IF, to refine diagnostic pathology as it is performed today. Individualized patient management requires a more comprehensive molecular profile of the actual tumor specimen in order to select appropriate therapeutics and define relevant parameters of prognosis. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aureon Biosciences Aureon Biosciences Aureon Biosciences Aureon Biosciences
Effect of EGFR mutations on gefitinib in advanced previous treated non-small-cell lung cancer
Authors: J. Guo, C. Zhou, Q. Deng, S. Ren, J. Zhang
Journal: Journal of Clinical Oncology (2008)

19132 Background: EGFR TKI has proved to be effective as second-line or third-line drug in advanced non-small cell lung cancer (NSCLC). EGFR mutations are associated with high response of NSCLC to EGFR TKI and may be with better survival. But it is difficult to get enough tissue for detection of the mutations in advance NSCLC patients. The purpose of the study was to detect EGFR mutations from plasma or pleural effusion and correlate the mutations with the efficacy of gefitinib. Methods: Advanced NSCLC patients failing in first-line chemotherapy or intolerable to chemotherapy were enrolled. The mutations of EGFR exons 19 and 21 were detected from their plasma or pleural effusions before gefitinib treatment with the method of real-time PCR usign TaqMan-MGB probe. The patients were given oral gefitinib 250mg/d up to disease progression or intolerable toxicity. Results: 89 advanced NSCLC entered into this study, including M/F: 55 vs 45%; Stage IIIb/IV: 98/2%; Adeno/Squa/other Ca.: 77.5/12.4/10.1%; PS 0–2/2–3: 57.3/42.7%; Smokers/non-smokers: 41.6/58.4%; first-line therapy/second-line therapy:25.8/74.2% with average age of 58 yrs old. Overall response rate and disease control rate were 29.2% and 63.6% respectively. The mutation rate was 21.4% in plasma (n=59) and 31.3% in pleural effusions (n=32). The response rate and disease control rate were 91% and 100% in EGFR mutant patients and 6% and 48% in EGFR wild-type patients (p<0.01). Progression free survival and median survival were 12 months and 15 months in EGFR mutant patients and 2.7 months and 5.7 months in wild-type patients (p<0.01) respectively. Mutation rate was 76.9% in patients with partial response, 6.7% in those with stable disease and 0% in those with disease progression. Toxicity was acceptable and similar in the patients with mutant EGFR and wild-type EGFR. Conclusion Detection of EGFR mutations with PCR by TaqMan-MGB probes in pleural effusions and plasma was feasible. EGFR mutant patients were highly responsive to gefitnib and get better survival benefit than wild-type patients. No significant financial relationships to disclose.
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth
Authors: M Okabe, Y Uehara, T Miyagishima, T Itaya, M Tanaka, Y Kuni-Eda, M Kurosawa, T Miyazaki
Journal: Blood (1992)
Longitudinal assessment of IL-6 and symptom severity in multiple myeloma patients during first 30 days of autologous BMT
Authors: X. S. Wang, S. Giralt, C. L. Warneke, T. R. Mendoza, M. Albitar, J. O. Brown, K. O. Anderson, C. S. Cleeland
Journal: Journal of Clinical Oncology (2004)

2616 Background: Patients with multiple myeloma (MM) who undergo auto-BMT develop numerous symptoms, including pain, fatigue, poor appetite, and disturbed sleep, at the nadir of transplantation. IL-6 plays a role in disease progression in MM. This pilot study prospectively assessed the relationship between changes in IL-6 and the severity of symptoms during the acute phase of auto-BMT. Methods: The M. D. Anderson Symptom Inventory (MDASI) was used to assess symptoms in 18 patients before and during the first 30 days post-transplantation. IL-6 was assayed pre-transplantation, at nadir, and at 30 days post-BMT. Results: Serum levels of IL-6 in MM patients were elevated before the BMT compared to non-cancer normal controls. IL-6 levels approximately tripled at nadir and returned almost to baseline level at 30 days. Symptom severity showed a similar increase, almost tripling at nadir and returning to near baseline by day 30. Conclusions: There appears to be a relationship between increased symptom severity and increased IL-6 levels during the acute phase of auto-BMT. The question of a causal link between cytokine levels and symptom severity requires further study and would be helped by more frequent assessment of IL-6 and other inflammatory cytokines. No significant financial relationships to disclose.
Abstract 14828: Voltage and Echo Mapping of Ventricular Tachycardia from Right Ventricular Outflow Tract: Common Myocardial Extensions Beyond the Pulmonic Valve as Sites of Origin
Authors: Christopher F Liu, George Thomas, Jim W Cheung, Steven M Markowitz, James E Ip, Bruce B Lerman
Journal: Circulation (2012)

Introduction Idiopathic ventricular tachycardia (VT) is commonly ablated in the RV outflow tract (RVOT). Electrogram amplitude is typically used to define the pulmonic valve (PV) plane, but this as...
Daily induction combination treatment with alfa2b interferon or standard combination treatment in naive chronic hepatitis C patients. A controlled multicenter randomized trail.
Authors: HR Van Vlierberghe, F Leroux-Roels, N Bourgeois, F Nevens, I Colie, J Henrion, J Delwaide, Y Horsmans, R Brenard, P Michielsen, Geert Robaeys, Liesbeth Bruckers
Journal: Hepatology (2000)
Squamous cell cancer of the head and neck (SCCHN) with distant metastasis at presentation
Authors: D. I. Kuperman, D. R. Adkins, V. Auethavekiat, B. Nussenbaum, K. Trinkaus, D. Morgensztern
Journal: Journal of Clinical Oncology (2008)

6053 Background: SCCHN is confined to the head and neck region in the majority of patients at presentation. Unfortunately, some patients have distant metastasis at presentation and this has a significant effect on treatment and prognosis. Current literature reports a rate of distant metastatic disease at presentation between 1.5% and 16.8%. This is based on small studies which preclude a more comprehensive analysis. We have studied the Surveillance Epidemiology and End Results (SEER) database to determine the rate of and risk factors for distant disease at presentation. Methods: We have identified all patients with the diagnosis of SCCHN who are older than age 20 who have been diagnosed between 1988 and 2003. Patients whose disease extent is not evaluated have been excluded. Tumor sites evaluated include the lip, oral cavity, oropharynx, nasopharynx, sinus, hypopharynx, supraglottis, glottis, and subglottis. In addition, we have determined the effect of lymph node status and primary size on the rate of distant metastases at presentation. We arbitrarily chose a rate of >5% to be high risk for metastasis and a rate of <1% to be low risk. The results were analyzed with binomial confidence intervals. Results: Among the 76,925 patients identified, 2,312 (3.01%; 95% CI: 2.89%-3.13%) had distant metastasis at presentation. The rate of distant metastases increased in relation to tumor size and lymph node status. Tumors at high risk include lip, hypopharynx, supraglottic, glottic, and nasopharynx N2/N3; lymph node positive sinus tumors; oropharynx and oral cavity tumors N3 disease; and sinus, hypopharynx, and oropharynx tumors greater than 4 cm. Tumors with low risk of metastasis include lip, oral cavity, and glottic tumors that are either less than 2 cm or without lymph node involvement. Conclusion: Distant metastasis at presentation is an uncommon event for SCCHN. The primary site, tumor size, and nodal stage all help determine the patients that are at particularly high or low risk for presenting with Stage IVC disease. Site Total in SEER Number Metastatic at Presentation Percentage 95% CI Lip 5,975 20 0.33% 0.20–0.52% Oral Cavity 16,385 320 1.95% 1.75–2.18% Oropharynx 17,783 729 4.10% 3.81–4.40% Hypopharynx 1,866 128 6.86% 5.75–8.10% Supraglottis 8,114 270 3.33% 2.95–3.74% Glottis 13,085 87 0.66% 0.53–0.82% Subglottis 356 12 3.37% 1.75–5.81% Sinus 1,068 69 6.46% 5.06–8.11% Nasopharynx 2,610 177 6.78% 5.85–7.81% No significant financial relationships to disclose.
WITHDRAWN: In vitro and in vivo evaluation of azilsartan tablets prepared by wet grinding combined with spray-drying and jet milling: Comparison with marketed tablets
Authors: Yinghua Sun, Cheng Gong, Zhonggui He
Journal: Asian Journal of Pharmaceutical Sciences (2015)

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies
Authors: Connor A Emdin, Christopher X Wong, Allan J Hsiao, Douglas G Altman, Sanne AE Peters, Mark Woodward, Ayodele A Odutayo
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To determine whether atrial fibrillation is a stronger risk factor for cardiovascular disease and death in women compared with men. <b>Design</b>&nbsp;Meta-analysis of cohort studies. <b>Data sources</b>&nbsp;Studies published between January 1966 and March 2015, identified through a systematic search of Medline and Embase and review of references. <b>Eligibility for selecting studies</b>&nbsp;Cohort studies with a minimum of 50 participants with and 50 without atrial fibrillation that reported sex specific associations between atrial fibrillation and all cause mortality, cardiovascular mortality, stroke, cardiac events (cardiac death and non-fatal myocardial infarction), and heart failure. <b>Data extraction</b>&nbsp;Two independent reviewers extracted study characteristics and maximally adjusted sex specific relative risks. Inverse variance weighted random effects meta-analysis was used to pool sex specific relative risks and their ratio. <b>Results</b>&nbsp;30 studies with 4 371 714 participants were identified. Atrial fibrillation was associated with a higher risk of all cause mortality in women (ratio of relative risks for women compared with men 1.12, 95% confidence interval 1.07 to 1.17) and a significantly stronger risk of stroke (1.99, 1.46 to 2.71), cardiovascular mortality (1.93, 1.44 to 2.60), cardiac events (1.55, 1.15 to 2.08), and heart failure (1.16, 1.07 to 1.27). Results were broadly consistent in sensitivity analyses. <b>Conclusion</b>&nbsp;Atrial fibrillation is a stronger risk factor for cardiovascular disease and death in women compared with men, though further research would be needed to determine any causality.
Comorbidity and survival of hepatocellular carcinoma patients at a VA medical canter
Authors: F. Zhong, T. Oliphant, V. T. Chang, B. Crump, M. L. Gonzalez, M. McPherson, E. Morales, L. Duque, J. Einhorn, B. Kasimis
Journal: Journal of Clinical Oncology (2009)

e15682 Background: To determine whether comorbidity indices predict survival in hepatocellular carcinoma (HCC) pts. Methods: In an IRB approved protocol, we reviewed the records of pts with tissue diagnosis of HCC seen at a VA Medical Center between 1/1/1999 to 12/31/2008. Comorbidity was assessed with four comorbidity indices, the Charlson Comorbidity Index (CMI), the Kaplan- Feinstein Index (KFI), the Cumulative Illness Rating Scale (CIRS), and VA Comorbidity Scale (VACS). Demographics, ECOG PS, stage, alpha-fetoprotein (AFP) at diagnosis, hepatitis B (HBV) and C (HCV) status, alcohol use, and iron overload were also reviewed. Cox survival regression analysis was performed. Results: There were 44 pts. All pts were men. The median (M) age at diagnosis was 60.5 years (range 35–86). The overall M survival was 230 days (4–2784). There were Stage I 12 (27%) pts, Stage II 7 (16%) pts, Stage III 14 (32%) pts, and Stage IV 11 (25%) pts. The M ECOG PS was 1.0 (0–4), stage 3 (1–4), CMI 5.75 (1–16), CIRS15 3.0 (1–5), CIRS16 6.0 (1–14), CIRS17 2.0 (0.83–5.0), CIRS18 0 (0–2), CIRS19 0 (0–1), KFI 3.0 (1–3), VACS 6.0 (2–9), and AFP 56.35 (1.1–379567). HBV was positive in 10 pts (23%), HCV 26 (59%) pts, alcohol use 37 (84%) pts, and iron overload 11 (25%) pts. In univariate survival analysis, stage (p&lt;.038), ECOG PS (p&lt;.001), AFP (p&lt;.009), presence of iron overload (p&lt;.006), and CMI (p&lt;.019) were significant in predicting survival. However, age, HBV, HCV, alcohol use, CIRS15, CIRS16, CIRS17, CIRS18, KFI, and VACS were not significant for survival. In multivariate survival analyses that included stage and a comorbidity index, the CMI approaches significance (p&lt;.077). Conclusions: In this sample, the CMI was a predictor for survival in pts with HCC. Further analysis in a larger sample is needed to provide a more definitive conclusion. This was supported by the New Jersey Commission for Cancer Research 09–1133-CCR-EO. No significant financial relationships to disclose.